41 unknown, 29 recruiting, 22 not yet recruiting, 21 completed. 49 Phase 2, 39 Phase 1, 19 Not applicable, 7 Early Phase 1, 6 Phase 3.
Follow Sichuan University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC) | Phase 2 | Not yet recruiting | Sichuan University | 30 | 2026-10-31 | 2026-05-05 |
| Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma [211At]MABG - Neuroblastoma (NB) | Early Phase 1 | Recruiting | Sichuan University | 10 | 2026-07-21 | 2026-08-21 |
| A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC SYS6010 - NSCLC | Phase 1 | Not yet recruiting | Sichuan University | 21 | 2026-06-30 | 2026-07-09 |
| Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study Neoplasms, Drug Therapy | Not yet recruiting | Sichuan University | 500 | 2026-06-30 | 2026-06-24 | |
| Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical Study Radiotherapy, Immune Checkpoint Inhibitors (ICIs) | Not yet recruiting | Sichuan University | 200 | 2026-06-30 | 2026-06-24 | |
| Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer ONVAX-01 plus Anti-PD-1 and Chemotherapy - Advanced Pancreatic Adenocarcinoma | Phase 1 | Not yet recruiting | Sichuan University | 9 | 2026-06-20 | 2026-06-10 |
| Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma fruquintinib + sintilimab + SOX, Sinitilimab+SOX - Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Sichuan University | 120 | 2026-06-15 | 2026-06-22 |
| Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel. - Esophageal Cancer | Completed | Sichuan University | 387 | 2026-04-01 | 2026-08-24 | |
| Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC PD-1 Inhibitor plus Chemotherapy, Oral Enteral Nutritional Preparation, Esophagectomy with lymph node dissection - Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sichuan University | 118 | 2026-04-01 | 2026-04-15 |
| Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Sacituzumab Tirumotecan and Anlotinib - Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Not yet recruiting | Sichuan University | 33 | 2026-04-01 | 2026-04-13 |
| Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | Completed | Sichuan University | 414 | 2026-03-01 | 2026-08-13 | |
| Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma Ivonescimab (20mg/kg Q3W), Oxaliplatin, S-1 - Gastric Cancer, RCT | Phase 2 | Not yet recruiting | Sichuan University | 154 | 2026-02-01 | 2026-01-28 |
| Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection WGb-0302 injection - Hematological Malignancies | Early Phase 1 | Not yet recruiting | Sichuan University | 20 | 2026-02-01 | 2026-01-23 |
| Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection WGb-0301 injection - B Cell Malignancies | Early Phase 1 | Not yet recruiting | Sichuan University | 9 | 2026-01-01 | 2026-01-12 |
| Low-Intensity Pulsed Ultrasound as an Adjunctive Therapy for Bone Regeneration Following Jaw Cyst Enucleation Low-Intensity Pulsed Ultrasound - Jaw Cysts, Curettage | Phase 3 | Not yet recruiting | Sadam Elayah | 29 | 2025-10-22 | 2025-10-07 |
| Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Trial Patient-Reported Outcome (PRO)-Based Symptom Management, Conventional Management - Esophageal Cancer (EsC) | Phase 3 | Not yet recruiting | Sichuan University | 240 | 2025-10-15 | 2025-10-07 |
| An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer Tislelizumab Injection - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Sichuan University | 21 | 2025-10-01 | 2025-03-19 |
| Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer recombinant human endostatin adenovirus, PD-1 Inhibitor - Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N) | Phase 1 | Not yet recruiting | Sichuan University | 40 | 2025-09-01 | 2025-09-04 |
| Lateral Positioning for Extubation After Adenotonsillectomy lateral postion, supine position - Perioperative Respiratory Adverse Events, Adenoidectomy | Not applicable | Not yet recruiting | Sichuan University | 350 | 2025-08-20 | 2025-08-06 |
| Oncolytic Virus in Esophageal Squamous Cell Carcinoma Oncolytic Virus: Administered via intratumoral injection (metastatic lesions in the neck or supraclavicular lymph nodes) once every 3 weeks, for a total of two to four doses., Oncolytic Virus: Administered via intratumoral injection (primary lesions) once every 3 weeks, for a total of two to four doses. - Esophageal Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan University | 40 | 2025-08-01 | 2025-12-08 |
Showing 20 of 121. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (13) · Esophageal Neoplasms (11) · Esophageal Squamous Cell Carcinoma (9) · Stomach Neoplasms (7) · Lung Neoplasms (6) · Small Cell Lung Carcinoma (5) · Leukemia, Lymphoid (3) · Carcinoma (2) · Hematologic Neoplasms (2) · Lymphoma, Extranodal NK-T-Cell (2) · Meningeal Carcinomatosis (2) · Neoplasms (2) · Neuroblastoma (2) · Pancreatic Neoplasms (2) · Pleural Effusion, Malignant (2)
Radiotherapy (13) · Drug Therapy (12) · Carboplatin (8) · Etoposide (8) · Immune Checkpoint Inhibitors (8) · sintilimab (8) · Cisplatin (6) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (6) · tislelizumab (6) · Gemcitabine (5) · Radiosurgery (5) · toripalimab (5) · Busulfan (4) · Cladribine (3) · Immunotherapy (3)
China (97) · Finland (1) · Hong Kong (1)
You Lu, MD (15) · Zhen-Yu Ding, Prof (4) · Ting Liu, MD (3) · Yongsheng Wang (3) · Jie Ji, MD (2) · Peng Liang, PhD (2) · Qiu Li, M.D. (2) · Rong Tian, MD (2) · Yongsheng Wang, Prof (2) · You Lu (2) · Bo Zhang, MD (1) · Gou Hongfeng (1) · Han Huang, M.D (1) · Heping Zhang, PHD (1)
PMID 37580090, PMID 10595609, PMID 11873920, PMID 16269373, PMID 16791967, PMID 17704786, PMID 18210181, PMID 20819983, PMID 21369751, PMID 23381675, PMID 24737677, PMID 25064681, PMID 25155453, PMID 25538264, PMID 25754329, PMID 25838375, PMID 25891174, PMID 26412456, PMID 27570942, PMID 27641687, PMID 28055103, PMID 28233802, PMID 28329770, PMID 28655015, PMID 28678778, PMID 28953676, PMID 29471520, PMID 30382872, PMID 31222771, PMID 31513484, PMID 32145206, PMID 32341578, PMID 32417411, PMID 32606208, PMID 32989632, PMID 33101409, PMID 33538338, PMID 33792646, PMID 33852952, PMID 34398971, PMID 34796431, PMID 35094890, PMID 35969830, PMID 36402752, PMID 36603169, PMID 37581611, PMID 37711905, PMID 37963317, PMID 38110039, PMID 38964333